Valuation
NBIXNeurocrine Biosciences Inc
StockNasdaq미국Health careEU retail: available
9/10
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | NBIX | Sector median | vs median |
|---|---|---|---|
| P/E | 19.6 | 28.8 · n=114 | 32% below |
| P/B | 3.7 | 3.0 · n=196 | 24% above |
| P/S | 4.1 | 3.7 · n=202 | 10% above |
| EV/EBIT | 16.9 | 24.1 · n=103 | 30% below |
| Free-cash-flow yield | — | 2.8% · n=187 | — |
| Dividend yield | 0.00% | 0.00% · n=215 | — |
| Return on equity | 22.1% | 2.7% · n=193 | 731% above |
| Return on invested capital | 20.6% | 3.5% · n=176 | 480% above |
| Gross margin | 98.0% | 62.5% · n=152 | 57% above |
| Net debt / EBITDA | −0.46 | 1.19 · n=108 | 139% below |
Value factor: 67 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| Instrument | P/E | P/B | EV/EBIT | Free-cash-flow yield | Dividend yield | Smart Score |
|---|---|---|---|---|---|---|
| LLYEli Lilly & Co | 42.6 | 33.6 | — | 1.6% | 0.6% | 6/10 |
| JNJJohnson & Johnson | 29.1 | 7.2 | — | 3.6% | 2.1% | 8/10 |
| ABBVAbbVie | 79.9 | — | 33.5 | 3.6% | 3.0% | 5/10 |
| MRKMerck | 114.6 | 8.7 | — | 4.4% | 2.3% | 8/10 |
| UNHUnitedHealth | 25.1 | 3.4 | 18.6 | 6.7% | 2.3% | 9/10 |
| TMOThermo Fisher Scientific | 35.7 | 4.7 | 35.2 | 2.9% | 0.3% | 8/10 |
| AMGNAmgen | 26.3 | 19.7 | 24.0 | 4.4% | 2.3% | 6/10 |
| GILDGILEAD | — | 16.1 | — | 6.8% | 2.1% | 4/10 |
| ABTAbbott | 28.5 | 3.4 | 26.8 | 4.1% | 3.0% | 5/10 |
| PFEPfizer | 38.4 | 2.0 | — | 6.6% | 5.9% | 1/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 6월 2026 · filed 31 7월 2026
여기서 계약 해지 · EU 소비자: 구매 후 14일 이내 취소 가능.